The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinico-genomic characterization of TP53/CDKN2A co-alteration and its prognostic value in biliary tract cancer (BTC).
 
Angelo Pirozzi
No Relationships to Disclose
 
Taro Shibuki
No Relationships to Disclose
 
Maria Fernanda Teixeira
No Relationships to Disclose
 
Celine Hoyek
No Relationships to Disclose
 
Naohiro Okano
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Lionel Aurelien Kankeu Fonkoua
Honoraria - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
 
Hani Babiker
Consulting or Advisory Role - Caris MPI; Celgene; Endocyte; Guardant Health; Idera; Incyte; Ipsen; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
Research Funding - AstraZeneca (Inst); BMS (Inst); Dragonfly Therapeutics (Inst); Elevation Oncology (Inst); HiFiBiO Therapeutics (Inst); Incyte (Inst); JSI (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Qurient (Inst); Revolution Health Care (Inst); Spirita Oncology (Inst); Strategia (Inst); Zelbio (Inst)
 
Mitsuho Imai
Patents, Royalties, Other Intellectual Property - 1. ?NCC's Reference: #2023-03 Filing number (Filing date): US 63/468,666 (2023.05.24) Title: METHOD OF USING AN ARTIFICIAL INTELLIGENCE-POWERED WHOLE SLIDE IMAGE (WSI) ANALYSIS TO PREDICT TUMOR RESPONSE TO SUBSEQUENT IMMUNE CHECKPOINT INHIBITOR TREATMEN
 
Chigusa Morizane
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Guardant Health; Konica Minolta; MSD K.K.; Myriad Genetics; Novartis; SERVIER; Sysmex; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Pfizer; Revolution Medicines; SERVIER; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo RD Novare (Inst); Eisai (Inst); EPS Corporation (Inst); Hitachi (Inst); LabCorp (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takao Fujisawa
Honoraria - Amelief; AstraZeneca; Merck Serono
 
Umair Majeed
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
 
Nguyen Tran
Consulting or Advisory Role - AstraZeneca (Inst); DAVA Oncology (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Ipsen (Inst); QED Therapeutics (Inst); TEMPUS (Inst)
Speakers' Bureau - DAVA oncology (Inst)
Research Funding - Exact Sciences
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Biologix FZC; Bristol-Myers Squibb Italy; Eisai; Eisai; Gilead Sciences; Guerbet; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Eisai; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Guerbet; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks; Zymeworks
Research Funding - Abbvie (Inst); Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Jazz Pharmaceuticals; Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; SERVIER (Inst); Taiho Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen; SERVIER
 
Pedro Uson Junior
No Relationships to Disclose
 
Mitesh Borad
Consulting or Advisory Role - Genentech; Guardant Health; Kriya Therapeutics; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Compass Therapeutics (Inst); Elevar Therapeutics (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Merck Serono (Inst); Nuvectis Pharma (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst); ZielBio (Inst)
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Exact Sciences; Guardant Health; Incyte; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis